The scientific and clinical validation hurdles for early-stage cancer screening are exceptionally high and will require significant time and resources.
Competition in the liquid biopsy and oncology diagnostics space is intense, with many well-funded players.
Maintaining an innovative, fast-moving startup culture post-IPO as the company scales can be challenging.
Opportunities Identified
Capturing a significant share of the multi-billion dollar minimal residual disease (MRD) testing market for post-surgery cancer patients.
The ultimate 'holy grail' opportunity of developing a widely adopted blood test for early-stage cancer screening in the general population.
Continued market share growth in the global prenatal genetic testing market.